

# John C Morris

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9724574/john-c-morris-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

430  
papers

76,732  
citations

118  
h-index

275  
g-index

451  
ext. papers

91,169  
ext. citations

8.8  
avg, IF

7.72  
L-index

#	Paper	IF	Citations
430	Beta-amyloid moderates the relationship between cortical thickness and attentional control in middle- and older-aged adults.. <i>Neurobiology of Aging</i> , <b>2022</b> , 112, 181-190	5.6	1
429	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
428	Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2022</b> , 1-13	2.1	3
427	Prion-like $\beta$ synuclein pathology in the brain of infants with Krabbe disease.. <i>Brain</i> , <b>2022</b> ,	11.2	2
426	A family of estimators to diagnostic accuracy when candidate tests are subject to detection limits-Application to diagnosing early stage Alzheimer disease.. <i>Statistical Methods in Medical Research</i> , <b>2022</b> , 9622802211072511	2.3	
425	Replication study of AD-associated rare variants.. <i>Alzheimer's and Dementia</i> , <b>2022</b> ,	1.2	
424	Variant-dependent heterogeneity in amyloid burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.. <i>Lancet Neurology</i> , <b>2022</b> , 21, 140-152	24.1	5
423	Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage.. <i>Neurobiology of Disease</i> , <b>2022</b> , 105662	7.5	1
422	Intracranial internal carotid artery calcification is not predictive of future cognitive decline.. <i>Alzheimer's Research and Therapy</i> , <b>2022</b> , 14, 32	9	1
421	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.. <i>Alzheimer's and Dementia</i> , <b>2022</b> ,	1.2	2
420	Dissection of the polygenic architecture of neuronal $A\beta$ production using a large sample of individual iPSC lines derived from Alzheimer's disease patients. <i>Nature Aging</i> , <b>2022</b> , 2, 125-139		0
419	Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease.. <i>Acta Neuropathologica Communications</i> , <b>2022</b> , 10, 29	7.3	0
418	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.. <i>Nature Communications</i> , <b>2022</b> , 13, 1495	17.4	0
417	Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	2
416	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression.. <i>JAMA Psychiatry</i> , <b>2022</b> ,	14.5	1
415	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.. <i>Lancet Neurology</i> , <b>2022</b> , 21, 329-341	24.1	4
414	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer's disease.. <i>Neurobiology of Disease</i> , <b>2022</b> , 105714	7.5	0

413	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease.. <i>NeuroImage</i> , <b>2022</b> , 119228	7.9	1
412	Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90.. <i>Scientific Reports</i> , <b>2022</b> , 12, 6117	4.9	1
411	Naturalistic driving measures of route selection associate with resting state networks in older adults.. <i>Scientific Reports</i> , <b>2022</b> , 12, 6486	4.9	0
410	Effect of Race on Prediction of Brain Amyloidosis by Plasma A $\beta$ 2/A $\beta$ 0, Phosphorylated Tau, and Neurofilament Ligh.. <i>Neurology</i> , <b>2022</b> ,	6.5	4
409	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267298	3.7	1
408	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 585	8.6	6
407	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. <i>Nature Communications</i> , <b>2021</b> , 12, 7065	17.4	2
406	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives.. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12226	6	1
405	Validation of AD8-Philippines (AD8-P): A Brief Informant-Based Questionnaire for Dementia Screening in the Philippines. <i>International Journal of Alzheimer's Disease</i> , <b>2021</b> , 2021, 7750235	3.7	0
404	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
403	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 80, 133-142	4.3	2
402	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. <i>Neurology: Genetics</i> , <b>2021</b> , 7, e571	3.8	7
401	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. <i>Brain</i> , <b>2021</b> , 144, 2176-2185	11.2	13
400	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. <i>Brain Connectivity</i> , <b>2021</b> , 11, 239-249	2.7	5
399	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 97, e76-e87	6.5	7
398	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. <i>Neurology</i> , <b>2021</b> , 96, e2546-e2557	6.5	12
397	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 396-406	17.2	41
396	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , <b>2021</b> , 32, 849-860	7.9	2

395	Network dysfunction in cognitively normal APOE $\epsilon$ carriers is related to subclinical tau. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	2
394	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	1
393	Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults. <i>Brain, Behavior, and Immunity</i> , <b>2021</b> , 94, 299-307	16.6	2
392	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. <i>Nature Communications</i> , <b>2021</b> , 12, 3825	17.4	9
391	GPS driving: a digital biomarker for preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 115	9	8
390	Cognitively normal APOE $\epsilon$ carriers have specific elevation of CSF SNAP-25. <i>Neurobiology of Aging</i> , <b>2021</b> , 102, 64-72	5.6	1
389	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , <b>2021</b> , 27, 1187-1196	50.5	51
388	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , <b>2021</b> , 16, 49	19	7
387	Comparing amyloid- $\beta$ plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. <i>Acta Neuropathologica</i> , <b>2021</b> , 142, 689-706	14.3	8
386	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. <i>Nature Neuroscience</i> , <b>2021</b> , 24, 1302-1312	25.5	9
385	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , <b>2021</b> , 89, 776-785	7.9	13
384	The BDNF SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 614-628	15.1	34
383	Evaluating Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent Variability. <i>Journal of Cognitive Neuroscience</i> , <b>2021</b> , 33, 279-302	3.1	2
382	Cerebrospinal fluid A $\beta$ 2 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability. <i>Neurobiology of Aging</i> , <b>2021</b> , 98, 116-123	5.6	2
381	Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 653-664	1.2	4
380	Item response theory analysis of the Clinical Dementia Rating. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 534-542		2
379	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. <i>JAMA Neurology</i> , <b>2021</b> , 78, 102-113	17.2	32
378	Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework. <i>Annals of Neurology</i> , <b>2021</b> , 89, 254-265	9.4	13

377	The Brain Chart of Aging: Machine-learning analytics reveals links between brain aging, white matter disease, amyloid burden, and cognition in the iSTAGING consortium of 10,216 harmonized MR scans. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 89-102	1.2	30
376	Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. <i>Brain</i> , <b>2021</b> ,	11.2	6
375	Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 559-572	4.3	3
374	Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 895-903	4.3	1
373	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12197	5.2	
372	Lack of association between acute stroke, post-stroke dementia, race, and $\beta$ amyloid status. <i>NeuroImage: Clinical</i> , <b>2021</b> , 29, 102553	5.3	5
371	Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 1009-1014	4.3	4
370	Lack of evidence supporting a role for DPP6 sequence variants in Alzheimer's disease in the European American population. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 623-624	14.3	1
369	The ideological divide in confidence in science and participation in medical research. <i>Scientific Reports</i> , <b>2021</b> , 11, 3120	4.9	2
368	Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 79, 1801-1811	4.3	4
367	Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 141-142	17.2	8
366	Spatially constrained kinetic modeling with dual reference tissues improves F-flortaucipir PET in studies of Alzheimer disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 3172-3186 <sup>1</sup>	8.8	1
365	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , <b>2021</b> , 53, 294-303	36.3	31
364	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. <i>Nature Communications</i> , <b>2021</b> , 12, 5346	17.4	6
363	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e050820	3	1
362	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	4
361	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 153	9	
360	Regional age-related atrophy after screening for preclinical alzheimer disease. <i>Neurobiology of Aging</i> , <b>2021</b> , 109, 43-51	5.6	1

359	Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. <i>Neurology</i> , <b>2021</b> , 97, e18236-e18345	6.1	5
358	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 483	8.6	3
357	Modeling autosomal dominant Alzheimer's disease with machine learning. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1005-1016	1.2	5
356	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. <i>Neurology</i> , <b>2021</b> , 96, e1632-e1645	6.5	4
355	Dopamine D1/D3 receptor density may correlate with parkinson disease clinical features. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 224-237	5.3	5
354	Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12103	6	5
353	Ante- and postmortem tau in autosomal dominant and late-onset Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2475-2480	5.3	4
352	Assessing the Reliability of Reported Medical History in Older Adults. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 78, 643-652	4.3	0
351	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , <b>2020</b> , 11, 2612	17.4	118
350	Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. <i>Cerebral Cortex</i> , <b>2020</b> , 30, 5686-5701	5.1	14
349	Addressing Health Disparities Among Minority Populations: Why Clinical Trial Recruitment Is Not Enough. <i>JAMA Neurology</i> , <b>2020</b> , 77, 1063-1064	17.2	30
348	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 1085-1095	4.3	10
347	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 1045-1055	4.3	14
346	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , <b>2020</b> , 142, 104960	7.5	15
345	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. <i>NeuroImage: Clinical</i> , <b>2020</b> , 26, 102248	5.3	7
344	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , <b>2020</b> , 26, 398-407	50.5	160
343	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 1119-1129	4.3	4
342	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12003	5.2	5

341	Spatial navigation ability predicts progression of dementia symptomatology. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 491-500	1.2	9
340	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 219-228	1.2	4
339	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. <i>Nature</i> , <b>2020</b> , 581, 71-76	50.4	356
338	A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 821-830	1.2	22
337	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 5	7.3	15
336	Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults. <i>SLEEP Advances</i> , <b>2020</b> , 1, zpa006	2.8	4
335	Functional connectivity among brain regions affected in Alzheimer's disease is associated with CSF TNF- $\alpha$ in APOE4 carriers. <i>Neurobiology of Aging</i> , <b>2020</b> , 86, 112-122	5.6	9
334	Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults. <i>Journal of Racial and Ethnic Health Disparities</i> , <b>2020</b> , 7, 269-280	3.5	2
333	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , <b>2020</b> , 19, 145-156	24.1	90
332	The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia. <i>Journal of the International Neuropsychological Society</i> , <b>2020</b> , 26, 596-606	3.1	11
331	Comparative Performance and Neuropathologic Validation of the AD8 Dementia Screening Instrument. <i>Alzheimer Disease and Associated Disorders</i> , <b>2020</b> , 34, 112-117	2.5	4
330	Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?. <i>Ageing Research Reviews</i> , <b>2020</b> , 57, 100994	12	28
329	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. <i>Neurobiology of Aging</i> , <b>2020</b> , 96, 165-175	5.6	1
328	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , <b>2020</b> , 2, fcaa102	4.5	6
327	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 57	19	16
326	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. <i>NeuroImage: Clinical</i> , <b>2020</b> , 28, 102491	5.3	4
325	Functional genomic analyses uncover APOE-mediated regulation of brain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. <i>Acta Neuropathologica Communications</i> , <b>2020</b> , 8, 196	7.3	4
324	Association of education with A $\beta$ burden in preclinical familial and sporadic Alzheimer disease. <i>Neurology</i> , <b>2020</b> , 95, e1554-e1564	6.5	2



323	Falls Associate with Neurodegenerative Changes in ATN Framework of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 745-752	4.3	6
322	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2020</b> , 96, 233-245	5.6	6
321	Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. <i>Neurology</i> , <b>2020</b> , 95, e3104-e3116	6.5	13
320	Relationships between big-five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12038	5.2	1
319	Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 1734-1744	1.2	7
318	Effect of escitalopram dose and treatment duration on CSF A $\beta$ levels in healthy older adults: A controlled clinical trial. <i>Neurology</i> , <b>2020</b> , 95, e2658-e2665	6.5	11
317	Microglia Implicated in Tauopathy in the Striatum of Neurodegenerative Disease Patients from Genotype to Phenotype. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
316	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1469-1482	4.3	4
315	Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning. <i>Alzheimer Disease and Associated Disorders</i> , <b>2020</b> , 34, 212-219	2.5	5
314	The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases. <i>Journal of Neurochemistry</i> , <b>2020</b> , 152, 235-251	6	8
313	The TMEM106B FTLN-protective variant, rs1990621, is also associated with increased neuronal proportion. <i>Acta Neuropathologica</i> , <b>2020</b> , 139, 45-61	14.3	21
312	Association between personality and tau-PET binding in cognitively normal older adults. <i>Brain Imaging and Behavior</i> , <b>2020</b> , 14, 2122-2131	4.1	11
311	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 501-511	1.2	20
310	Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , <b>2020</b> , 16, 589-597	1.2	6
309	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1448-1457	1.2	3
308	Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 450-457	6	1
307	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. <i>Nature Medicine</i> , <b>2019</b> , 25, 277-283	50.5	375
306	Persistent metabolic youth in the aging female brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 3251-3255	11.5	72



305	Higher Body Mass Index Is Associated with Lower Cortical Amyloid- $\beta$ Burden in Cognitively Normal Individuals in Late-Life. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 69, 817-827	4.3	9
304	Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia. <i>Alzheimer Disease and Associated Disorders</i> , <b>2019</b> , 33, 87-94	2.5	25
303	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. <i>Archives of Clinical Neuropsychology</i> , <b>2019</b> , 34, 1138-1155	2.7	7
302	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 18	19	32
301	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2019</b> , 142, 1429-1440	11.2	22
300	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 655-665	1.2	48
299	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , <b>2019</b> , 92, e1567-e1579	6.5	40
298	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2019</b> , 22, 101767	5.3	16
297	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 180-190	5.2	46
296	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , <b>2019</b> , 127, 492-501	5.1	15
295	Multi-Modal Home Sleep Monitoring in Older Adults. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	5
294	High-precision plasma $\beta$ amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , <b>2019</b> , 93, e1647-e1659	6.5	245
293	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 71	9	66
292	Translocator protein in late stage Alzheimer's disease and Dementia with Lewy bodies brains. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1423-1434	5.3	16
291	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1149-1159	1.2	24
290	Neuroinflammation and Myelin Status in Alzheimer's Disease, Parkinson's Disease, and Normal Aging Brains: A Small Sample Study. <i>Parkinson's Disease</i> , <b>2019</b> , 2019, 7975407	2.6	14
289	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , <b>2019</b> , 86, 616-625	9.4	13
288	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1913491	10.4	7

287	Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , <b>2019</b> , 33, 15-20	2.5	8
286	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. <i>Nature Genetics</i> , <b>2019</b> , 51, 414-430	36.3	917
285	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 506-514	1.2	10
284	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , <b>2019</b> , 142, 1063-1076	11.2	71
283	IC-P-021: LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD <b>2019</b> , 15, P29-P29		1
282	Adaptation of the Clinical Dementia Rating Scale for adults with Down syndrome. <i>Journal of Neurodevelopmental Disorders</i> , <b>2019</b> , 11, 39	4.6	4
281	Driving in the elderly in health and disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2019</b> , 167, 563-573	3	4
280	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. <i>Nature Neuroscience</i> , <b>2019</b> , 22, 1903-1912	25.5	118
279	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1917126	10.4	15
278	Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	123
277	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. <i>JAMA Neurology</i> , <b>2019</b> , 76, 264-273	7.2	117
276	Seizures as an early symptom of autosomal dominant Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2019</b> , 76, 18-23	5.6	19
275	Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. <i>Nature Medicine</i> , <b>2019</b> , 25, 270-276	50.5	577
274	Tau Positron Emission Tomography Binding Is Not Elevated in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 68-72	7	5
273	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , <b>2019</b> , 75, 223.e1-223.e10	5.6	10
272	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 106-152	1.2	153
271	Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network. <i>Neurobiology of Aging</i> , <b>2019</b> , 75, 42-50	5.6	26
270	Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , <b>2019</b> , 121, 327-337	7.5	52

269	A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study. <i>Journal of Applied Gerontology</i> , <b>2019</b> , 38, 277-289	3.3	15
268	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 1186-1200	11.2	54
267	Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1460-1469	1.2	120
266	Proximity to Parental Symptom Onset and Amyloid Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2018</b> , 75, 608-619	17.2	16
265	Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing. <i>Brain</i> , <b>2018</b> , 141, 1486-1500	11.2	46
264	Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 745-756	4.3	29
263	Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE $\epsilon$ genotype. <i>Brain</i> , <b>2018</b> , 141, 1828-1839	11.2	53
262	Reply to "Excess amyloid beta can be degraded in healthy humans". <i>Annals of Neurology</i> , <b>2018</b> , 83, 650-654		
261	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 241-250	24.1	224
260	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , <b>2018</b> , 75, 582-590	17.2	166
259	Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 10-17	2.5	174
258	In vivo [ $^{18}$ F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , <b>2018</b> , 90, e896-e906		20
257	Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies. <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 179-184	2.5	1
256	Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 610-616	1.2	6
255	Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid $\beta$ positron emission tomography pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 245-252	5.2	34
254	Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities. <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 101-106	2.5	9
253	Prevalence of the apolipoprotein E $\epsilon$ allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
252	Data-driven models of dominantly-inherited Alzheimer's disease progression. <i>Brain</i> , <b>2018</b> , 141, 1529-1544	11.2	66

251	Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 67, 95-98	5.6	40
250	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: Aβ serial magnetic resonance imaging study. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 43-53	1.2	28
249	Upward drift in cerebrospinal fluid amyloid β2 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 62-70	1.2	36
248	Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 205-214	1.2	70
247	Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e859-e866	6.5	116
246	Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 69	9	11
245	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. <i>Frontiers in Neuroscience</i> , <b>2018</b> , 12, 209	5.1	10
244	Using the A/T/N Framework to Examine Driving in Preclinical AD. <i>Geriatrics (Switzerland)</i> , <b>2018</b> , 3,	2.2	4
243	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. <i>Genome Medicine</i> , <b>2018</b> , 10, 43	14.4	26
242	Effect of BDNF Val66Met on disease markers in dominantly inherited Alzheimer's disease. <i>Annals of Neurology</i> , <b>2018</b> , 84, 424-435	9.4	14
241	Discovery and validation of autosomal dominant Alzheimer's disease mutations. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 67	9	16
240	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195838	3.7	34
239	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 509-513	4.3	4
238	Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 351-358	2.5	107
237	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
236	Estimating diagnostic accuracy for clustered ordinal diagnostic groups in the three-class case-Application to the early diagnosis of Alzheimer disease. <i>Statistical Methods in Medical Research</i> , <b>2018</b> , 27, 701-714	2.3	1
235	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , <b>2018</b> , 17, 64-74	24.1	121
234	Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. <i>Annals of Neurology</i> , <b>2018</b> , 83, 197-204	9.4	147

233	P3-251: SERUM NEUROFILAMENT LIGHT CHAIN LEVELS ARE ASSOCIATED WITH CSF NEUROFILAMENT LIGHT CHAIN, COGNITIVE STATUS, AND DISEASE PROGRESSION IN AUTOSOMAL DOMINANT AD <b>2018</b> , 14, P1170-P1170		1
232	P4-108: RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE <b>2018</b> , 14, P1480-P1480		3
231	Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. <i>Alzheimer Disease and Associated Disorders</i> , <b>2018</b> , 32, 291-297	2.5	6
230	The relevance of cerebrospinal fluid $\beta$ -synuclein levels to sporadic and familial Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , <b>2018</b> , 6, 130	7.3	24
229	CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	41
228	Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 669-677	5.2	11
227	Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 1213-1221	4.3	5
226	O1-04-03: COMPARING SMARTPHONE-ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE <b>2018</b> , 14, P224-P225		4
225	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2018</b> , 4, 669-676	6	6
224	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 98	9	19
223	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2018</b> , 141, 3065-3080	11.2	72
222	Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease. <i>Annals of Neurology</i> , <b>2018</b> , 84, 741-753	9.4	10
221	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1427-1437	1.2	31
220	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , <b>2018</b> , 141, 3233-3248	11.2	15
219	P1-288: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)-ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES <b>2018</b> , 14, P395-P396		1
218	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e1295-e1306	6.5	129
217	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 72, 177-185	5.6	26
216	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 406-416	5.3	37

215	Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions. <i>Neurology</i> , <b>2018</b> , 91, e313-e318	6.5	43
214	Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. <i>Alzheimer Disease and Associated Disorders</i> , <b>2017</b> , 31, 69-72	2.5	25
213	Preclinical Alzheimer's disease and longitudinal driving decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 74-82	6	25
212	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. <i>Neurology</i> , <b>2017</b> , 88, 1273-1281	6.5	23
211	Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. <i>Acta Neuropathologica</i> , <b>2017</b> , 133, 839-856	14.3	107
210	Transethnic genome-wide scan identifies novel Alzheimer's disease loci. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 727-738	1.2	106
209	Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnesic Alzheimer Disease Dementia. <i>Alzheimer Disease and Associated Disorders</i> , <b>2017</b> , 31, 87-93	2.5	37
208	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 56, 25-32	5.6	36
207	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 1197-1206	1.2	32
206	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 1225	4.9	32
205	Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 58, 675-680	4.3	8
204	A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 147-155	5.2	15
203	Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, e1-e85	1.2	157
202	Latent structure of cognitive performance in the adult children study. <i>Journal of Clinical and Experimental Neuropsychology</i> , <b>2017</b> , 39, 621-635	2.1	3
201	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 561-571	1.2	137
200	In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. <i>NeuroImage</i> , <b>2017</b> , 148, 296-304	7.9	37
199	Associations Between $\beta$ Amyloid Kinetics and the $\beta$ Amyloid Diurnal Pattern in the Central Nervous System. <i>JAMA Neurology</i> , <b>2017</b> , 74, 207-215	17.2	33
198	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 60	9	197



197	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. <i>Nature</i> , <b>2017</b> , 549, 523-527	50.4	520
196	Amyloid $\beta$ concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 841-849	1.2	266
195	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 1373-1384	36.3	508
194	Loss of Brain Aerobic Glycolysis in Normal Human Aging. <i>Cell Metabolism</i> , <b>2017</b> , 26, 353-360.e3	24.6	121
193	AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. <i>NeuroImage</i> , <b>2017</b> , 161, 171-178	7.9	76
192	[P3063]: MOTOR SYMPTOMS IN FAMILIAL ALZHEIMER'S DISEASE: FREQUENCY, SEVERITY AND PREDICTIVE VALUE <b>2017</b> , 13, P1043-P1044		
191	Factors Influencing Successful Lumbar Puncture in Alzheimer Research. <i>Alzheimer Disease and Associated Disorders</i> , <b>2017</b> , 31, 287-294	2.5	11
190	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. <i>PLoS Genetics</i> , <b>2017</b> , 13, e1007045	6	19
189	Cerebrospinal Fluid A $\beta$ 2/40 Corresponds Better than A $\beta$ 2 to Amyloid PET in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 813-822	4.3	120
188	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , <b>2016</b> , 21, 108-17	15.1	175
187	Longitudinal $\beta$ Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1192-1200	17.2	63
186	BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. <i>Brain</i> , <b>2016</b> , 139, 2766-2777	11.2	48
185	Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between $\beta$ Amyloid and Tauopathy. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1070-7	17.2	179
184	Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. <i>Annals of Neurology</i> , <b>2016</b> , 80, 379-87	9.4	65
183	Tau and A $\beta$ imaging, CSF measures, and cognition in Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 338ra66	17.5	418
182	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). <i>Lancet Neurology</i> , <b>2016</b> , 15, 1317-1325	24.1	64
181	The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. <i>Brain</i> , <b>2016</b> , 139, 2249-60	11.2	125
180	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. <i>Annals of Neurology</i> , <b>2016</b> , 79, 929-39	9.4	247

179	Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. <i>Neurology</i> , <b>2016</b> , 86, 1499-506	6.5	27
178	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , <b>2016</b> , 12, 614-22	1.2	30
177	Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2016</b> , 73, 561-71	17.2	118
176	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. <i>Neurobiology of Aging</i> , <b>2016</b> , 37, 208.e1-208.e9	5.6	29
175	Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2016</b> , 38, 104-111	5.6	10
174	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. <i>F1000Research</i> , <b>2016</b> , 5, 2376	3.6	21
173	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152082	3.7	31
172	Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. <i>F1000Research</i> , <b>2016</b> , 5, 2376	3.6	23
171	Comparison of a single-channel EEG sleep study to polysomnography. <i>Journal of Sleep Research</i> , <b>2016</b> , 25, 625-635	5.8	68
170	Spatial Navigation in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 77-90	4.3	101
169	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. <i>Scientific Reports</i> , <b>2016</b> , 6,	4.9	20
168	Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 369ra178	17.5	155
167	IC-01-03: Classifying TAU Pet Positivity With [18F]-AV-1451 in Preclinical Alzheimer's Disease <b>2016</b> , 12, P2-P3		2
166	O2-03-02: are White Matter Hyperintensities a Core Feature of Alzheimer's Disease or Just a Reflection of Amyloid Angiopathy? Evidence From the Dominantly Inherited Alzheimer Network (DIAN) <b>2016</b> , 12, P226-P226		1
165	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network <b>2016</b> , 12, P378-P379		
164	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. <i>Neurobiology of Aging</i> , <b>2016</b> , 43, 23-33	5.6	35
163	Assessment of the genetic variance of late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2016</b> , 41, 200.e13-200.e20	5.6	119
162	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. <i>Neurobiology of Aging</i> , <b>2016</b> , 44, 1-8	5.6	65

161	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. <i>American Journal of Geriatric Psychiatry</i> , <b>2016</b> , 24, 1095-1104	6.5	58
160	Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1125-32	17.2	12
159	Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. <i>Brain</i> , <b>2015</b> , 138, 1036-45	11.2	54
158	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, e1-120	1.2	206
157	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 865-84	1.2	132
156	Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1029-42	17.2	190
155	Tailored Calendar Journals to Ascertain Falls Among Older Adults. <i>OTJR Occupation, Participation and Health</i> , <b>2015</b> , 35, 53-9	1.3	8
154	Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 656-65	17.2	66
153	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
152	"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. <i>Neurology</i> , <b>2015</b> , 84, 617-23	26.5	101
151	Spatially distinct atrophy is linked to amyloid and tau in preclinical Alzheimer disease. <i>Neurology</i> , <b>2015</b> , 84, 1254-60	6.5	51
150	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1771-9	5.6	30
149	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 59	9	80
148	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. <i>Neurology</i> , <b>2015</b> , 85, 790-8	6.5	23
147	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1275-80	17.2	152
146	Partial volume correction in quantitative amyloid imaging. <i>NeuroImage</i> , <b>2015</b> , 107, 55-64	7.9	138
145	At the interface of sensory and motor dysfunctions and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2015</b> , 11, 70-98	1.2	271
144	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. <i>Journal of the International Neuropsychological Society</i> , <b>2015</b> , 21, 573-83	3.1	23

143	P2-130: Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease <b>2015</b> , 11, P533-P534		1
142	Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropathology</i> , <b>2015</b> , 35, 390-400	2	47
141	Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. <i>Neuropsychology</i> , <b>2015</b> , 29, 368-81	3.8	23
140	Absence of practice effects in preclinical Alzheimer's disease. <i>Neuropsychology</i> , <b>2015</b> , 29, 940-8	3.8	73
139	Age and amyloid effects on human central nervous system amyloid-beta kinetics. <i>Annals of Neurology</i> , <b>2015</b> , 78, 439-53	9.4	98
138	Quantitative amyloid imaging using image-derived arterial input function. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122920	3.7	20
137	Clinical Features of Alzheimer Disease With and Without Lewy Bodies. <i>JAMA Neurology</i> , <b>2015</b> , 72, 789-96	7.2	50
136	Factors associated with the onset and persistence of post-lumbar puncture headache. <i>JAMA Neurology</i> , <b>2015</b> , 72, 325-32	17.2	43
135	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. <i>NeuroImage: Clinical</i> , <b>2015</b> , 8, 246-52	5.3	32
134	Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1484-90	17.2	30
133	Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). <i>Neuropsychology</i> , <b>2014</b> , 28, 19-29	3.8	48
132	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , <b>2014</b> , 505, 550-554	50.4	345
131	Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging. <i>Neurology</i> , <b>2014</b> , 83, 1613-9	6.5	40
130	Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. <i>Neurology</i> , <b>2014</b> , 83, 253-60	6.5	266
129	Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. <i>Current Neurology and Neuroscience Reports</i> , <b>2014</b> , 14, 499	6.6	52
128	Phosphorylated tau-A $\beta$ 2 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. <i>Biological Psychiatry</i> , <b>2014</b> , 75, 723-31	7.9	58
127	Missense variant in TREML2 protects against Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 1510.e19-2684	6.1	64
126	Genome-wide association study of CSF levels of 59 Alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. <i>PLoS Genetics</i> , <b>2014</b> , 10, e1004758	6	84

125	Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 226ra30	17.5	244
124	Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. <i>Alzheimer Disease and Associated Disorders</i> , <b>2014</b> , 28, 50-7	2.5	26
123	An antidepressant decreases CSF A $\beta$ production in healthy individuals and in transgenic AD mice. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 236re4	17.5	111
122	Functional connectivity in autosomal dominant and late-onset Alzheimer disease. <i>JAMA Neurology</i> , <b>2014</b> , 71, 1111-22	17.2	68
121	Functional connectivity and graph theory in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 757-68	5.6	230
120	Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. <i>PLoS ONE</i> , <b>2014</b> , 9, e89998	3.7	36
119	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, E4502-9	11.5	253
118	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 65	7.3	110
117	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. <i>Lancet Neurology</i> , <b>2013</b> , 12, 957-65	24.1	389
116	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, e111-94	1.2	296
115	The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. <i>NeuroImage</i> , <b>2013</b> , 76, 332-44	7.9	140
114	Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, S39-44	1.2	67
113	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. <i>Neuron</i> , <b>2013</b> , 78, 256-68	13.9	255
112	Sleep quality and preclinical Alzheimer disease. <i>JAMA Neurology</i> , <b>2013</b> , 70, 587-93	17.2	414
111	Cerebrospinal fluid A $\beta$ 2, phosphorylated Tau181, and resting-state functional connectivity. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1242-8	17.2	68
110	The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. <i>Neurology</i> , <b>2013</b> , 81, 1425-33	6.5	56
109	Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. <i>Neuropsychology</i> , <b>2013</b> , 27, 516-28	3.8	37
108	Preclinical Alzheimer disease and risk of falls. <i>Neurology</i> , <b>2013</b> , 81, 437-43	6.5	53

107	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. <i>Neurology</i> , <b>2013</b> , 81, 736-44	6.5	115
106	The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE- $\epsilon$ 4 carriers. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003685	6	49
105	Increased in vivo amyloid- $\beta$ 2 production, exchange, and loss in presenilin mutation carriers. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 189ra77	17.5	144
104	Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. <i>Neurology</i> , <b>2013</b> , 80, 1784-91	6.5	175
103	Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. <i>Alzheimer's Research and Therapy</i> , <b>2013</b> , 5, 48	9	100
102	Quantitative analysis of PiB-PET with FreeSurfer ROIs. <i>PLoS ONE</i> , <b>2013</b> , 8, e73377	3.7	126
101	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <i>Neurology</i> , <b>2012</b> , 79, 897-905	6.5	175
100	Clinical and biomarker changes in dominantly inherited Alzheimer's disease. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 795-804	59.2	2272
99	The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. <i>Alzheimer's and Dementia</i> , <b>2012</b> , 8, S1-68	1.2	368
98	Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 4558-71	5.6	150
97	Toward a multifactorial model of Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 2262-71	5.6	42
96	PET amyloid-beta imaging in preclinical Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2012</b> , 1822, 370-9	6.9	102
95	Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. <i>Archives of Neurology</i> , <b>2012</b> , 69, 700-8		110
94	Effects of age and amyloid deposition on A $\beta$ dynamics in the human central nervous system. <i>Archives of Neurology</i> , <b>2012</b> , 69, 51-8		185
93	Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 8890-9	6.6	385
92	Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. <i>Archives of Neurology</i> , <b>2012</b> , 69, 636-43		196
91	Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , <b>2012</b> , 2, 975-984		144
90	Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 362-81	3.1	1145



89	Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. <i>Neurobiology of Aging</i> , <b>2011</b> , 32 Suppl 1, S1-3	5.6	28
88	The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2011</b> , 7, 263-9	1.2	8211
87	Role of family history for Alzheimer biomarker abnormalities in the adult children study. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1313-9		46
86	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. <i>Nature Genetics</i> , <b>2011</b> , 43, 436-41	36.3	1367
85	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2011</b> , 43, 429-35	36.3	1421
84	Alzheimer's disease: the challenge of the second century. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 77sr1	17.5	893
83	Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. <i>Annals of Neurology</i> , <b>2011</b> , 70, 274-85	9.4	113
82	Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. <i>Annals of Neurology</i> , <b>2011</b> , 70, 857-61	9.4	118
81	Relationship between late-life hypertension, blood pressure, and Alzheimer's disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2011</b> , 26, 457-62	2.5	27
80	Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1013-9		87
79	Human apoE isoforms differentially regulate brain amyloid- $\beta$ peptide clearance. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 89ra57	17.5	721
78	Comparison of analytical platforms for cerebrospinal fluid measures of amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. <i>Archives of Neurology</i> , <b>2011</b> , 68, 1137-44		138
77	An interdisciplinary outreach model of African American recruitment for Alzheimer's disease research. <i>Gerontologist, The</i> , <b>2011</b> , 51 Suppl 1, S134-41	5	38
76	Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. <i>Archives of Neurology</i> , <b>2011</b> , 68, 581-6		119
75	Serotonin signaling is associated with lower amyloid- $\beta$ levels and plaques in transgenic mice and humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 14968-73	11.5	218
74	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , <b>2010</b> , 42, 234-9	36.3	361
73	SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. <i>PLoS Genetics</i> , <b>2010</b> , 6, e1001101	6	90
72	Barriers and facilitators of African American participation in Alzheimer disease biomarker research. <i>Alzheimer Disease and Associated Disorders</i> , <b>2010</b> , 24 Suppl, S24-9	2.5	61

71	Relationship of dementia screening tests with biomarkers of Alzheimer's disease. <i>Brain</i> , <b>2010</b> , 133, 3290-300	77
70	Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. <i>Archives of Neurology</i> , <b>2010</b> , 67, 1473-84	330
69	Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. <i>Biological Psychiatry</i> , <b>2010</b> , 67, 581-3	7.9 19
68	YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. <i>Biological Psychiatry</i> , <b>2010</b> , 68, 903-12	7.9 298
67	Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. <i>Alzheimer's and Dementia</i> , <b>2010</b> , 6, 239-46	1.2 308
66	Decreased clearance of CNS beta-amyloid in Alzheimer's disease. <i>Science</i> , <b>2010</b> , 330, 1774	33.3 1349
65	Spatial correlation between brain aerobic glycolysis and amyloid- $\beta$ deposition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 17763-7	11.5 275
64	Ascertainment bias in the clinical diagnosis of Alzheimer disease. <i>Archives of Neurology</i> , <b>2010</b> , 67, 1364-9	29
63	APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. <i>Annals of Neurology</i> , <b>2010</b> , 67, 122-31	9.4 618
62	Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. <i>Annals of Neurology</i> , <b>2010</b> , 68, 311-8	9.4 205
61	Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1476-81	247
60	Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. <i>Archives of Neurology</i> , <b>2009</b> , 66, 638-45	148
59	Stability of the Clinical Dementia Rating, 1979-2007. <i>Archives of Neurology</i> , <b>2009</b> , 66, 773-7	29
58	Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1557-62	165
57	The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. <i>Cerebral Cortex</i> , <b>2009</b> , 19, 497-510	5.1 669
56	The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. <i>Neurology</i> , <b>2009</b> , 72, 1048-55	6.5 213
55	Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1469-75	350
54	Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. <i>Annals of Neurology</i> , <b>2009</b> , 65, 176-83	9.4 272

53	Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. <i>EMBO Molecular Medicine</i> , <b>2009</b> , 1, 371-80	12	278
52	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. <i>Nature Genetics</i> , <b>2009</b> , 41, 1088-93	36.3	2018
51	Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 432-40	5.6	203
50	Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , <b>2009</b> , 30, 1026-36	5.6	485
49	The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. <i>Alzheimer Disease and Associated Disorders</i> , <b>2009</b> , 23, 91-101	2.5	525
48	Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 4441-6	11.5	407
47	Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. <i>Archives of Neurology</i> , <b>2008</b> , 65, 1467-71		163
46	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. <i>Annals of Neurology</i> , <b>2007</b> , 61, 446-53	9.4	67
45	Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. <i>Neurology</i> , <b>2007</b> , 68, 666-9	6.5	201
44	Evaluation of cognitive impairment in older adults: combining brief informant and performance measures. <i>Archives of Neurology</i> , <b>2007</b> , 64, 718-24		48
43	Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. <i>Archives of Neurology</i> , <b>2007</b> , 64, 725-30		120
42	Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. <i>Archives of Neurology</i> , <b>2007</b> , 64, 343-9		727
41	The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. <i>Alzheimer Disease and Associated Disorders</i> , <b>2007</b> , 21, 249-58	2.5	397
40	TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. <i>American Journal of Pathology</i> , <b>2007</b> , 171, 227-40	5.8	376
39	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. <i>Annals of Neurology</i> , <b>2006</b> , 59, 512-9	9.4	1009
38	Accelerated weight loss may precede diagnosis in Alzheimer disease. <i>Archives of Neurology</i> , <b>2006</b> , 63, 1312-7		230
37	Validity and reliability of the AD8 informant interview in dementia. <i>Neurology</i> , <b>2006</b> , 67, 1942-8	6.5	272
36	Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. <i>Neurology</i> , <b>2006</b> , 67, 467-73	6.5	231

35	The neuropathology of Alzheimer disease in African American and white individuals. <i>Archives of Neurology</i> , <b>2006</b> , 63, 87-90		29
34	The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. <i>Alzheimer Disease and Associated Disorders</i> , <b>2006</b> , 20, 210-6	2.5	568
33	Measuring and estimating diagnostic accuracy when there are three ordinal diagnostic groups. <i>Statistics in Medicine</i> , <b>2006</b> , 25, 1251-73	2.3	71
32	Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 7709-17	6.6	1550
31	Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. <i>Archives of Neurology</i> , <b>2005</b> , 62, 1821-30		102
30	Clinician assessment of the driving competence of patients with dementia. <i>Journal of the American Geriatrics Society</i> , <b>2005</b> , 53, 829-33	5.6	51
29	Driving and dementia of the Alzheimer type: beliefs and cessation strategies among stakeholders. <i>Gerontologist</i> , <b>2005</b> , 45, 676-85	5	63
28	Antecedent biomarkers of Alzheimer's disease: the adult children study. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2005</b> , 18, 242-4	3.8	28
27	A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. <i>NeuroImage</i> , <b>2004</b> , 23, 724-38	7.9	905
26	Absence of effect of depression on cognitive performance in early-stage Alzheimer disease. <i>Archives of Neurology</i> , <b>2004</b> , 61, 1265-8		18
25	Longitudinal driving performance in early-stage dementia of the Alzheimer type. <i>Journal of the American Geriatrics Society</i> , <b>2003</b> , 51, 1342-7	5.6	185
24	Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. <i>Journal of the American Geriatrics Society</i> , <b>2003</b> , 51, 819-23	5.6	63
23	Functional deactivations: change with age and dementia of the Alzheimer type. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 14504-9	11.5	602
22	Rates of progression in mild cognitive impairment and early Alzheimer's disease. <i>Neurology</i> , <b>2002</b> , 59, 1034-41	6.5	182
21	Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. <i>Journal of Molecular Neuroscience</i> , <b>2001</b> , 17, 101-18	3.3	359
20	Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. <i>Archives of Neurology</i> , <b>2001</b> , 58, 1395-402		433
19	Mild cognitive impairment represents early-stage Alzheimer disease. <i>Archives of Neurology</i> , <b>2001</b> , 58, 397-405		1179
18	Current concepts in mild cognitive impairment. <i>Archives of Neurology</i> , <b>2001</b> , 58, 1985-92		3473

17	Interrater reliability of the Clinical Dementia Rating in a multicenter trial. <i>Journal of the American Geriatrics Society</i> , <b>2000</b> , 48, 558-9	5.6	54
16	Differences in the A $\beta$ <sub>40</sub> /A $\beta$ <sub>42</sub> ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. <i>Annals of Neurology</i> , <b>2000</b> , 48, 201-210	9.4	110
15	Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. <i>Annals of Neurology</i> , <b>1999</b> , 45, 358-68	9.4	1360
14	Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. <i>Nature</i> , <b>1998</b> , 393, 702-5	50.4	2903
13	Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. <i>Archives of Neurology</i> , <b>1998</b> , 55, 326-35		579
12	Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. <i>International Psychogeriatrics</i> , <b>1997</b> , 9 Suppl 1, 173-6; discussion 177-8	3.4	888
11	Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>1996</b> , 16, 4491-500	6.6	1359
10	The Clinical Dementia Rating (CDR): current version and scoring rules. <i>Neurology</i> , <b>1993</b> , 43, 2412-4	6.5	6096
9	A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1253-9	59.2	546
8	Brief screening tests versus clinical staging in senile dementia of the Alzheimer type. <i>Journal of the American Geriatrics Society</i> , <b>1990</b> , 38, 129-35	5.6	69
7	Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. <i>Annals of Neurology</i> , <b>1988</b> , 23, 477-84	9.4	151
6	Validation of clinical diagnostic criteria for Alzheimer's disease. <i>Annals of Neurology</i> , <b>1988</b> , 24, 17-22	9.4	327
5	OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease		81
4	Functional brain age prediction suggests accelerated aging in preclinical familial Alzheimer's disease, irrespective of fibrillar amyloid-beta pathology		3
3	Genomic and multi-tissue proteomic integration for understanding the biology of disease and other complex traits		9
2	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain		1
1	Neuroimaging within the Dominantly Inherited Alzheimer's Network (DIAN): PET and MRI		1